Trials in Boston, Massachusetts
Here are the top 10 medical studies for alzheimer's disease in Boston, Massachusetts
Popular Filters
Phase 3 Trials
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Methuen, Massachusetts
This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Methuen, Massachusetts
This trial is testing whether semaglutide has a positive effect on early Alzheimer's disease by comparing it to a placebo. There will be 17 clinic visits and 1 phone call with the study doctor, and various tests and scans will be performed. The study will last for up to 173 weeks.
Monoclonal Antibodies
Lecanemab for Alzheimer's Disease
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial is testing lecanemab, a drug aimed at improving memory and thinking skills in people with early signs of Alzheimer's disease. The drug works by reducing amyloid plaques in the brain, which are believed to contribute to Alzheimer's. Researchers want to see if lecanemab is effective over several years.
Monoclonal Antibodies
Donanemab for Early Alzheimer's Disease
Recruiting1 awardPhase 3
New Haven, Connecticut
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Monoclonal Antibodies
Donanemab for Alzheimer's Disease
Recruiting1 awardPhase 3
Newton, Massachusetts
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Trials With No Placebo
[18F]3F4AP Imaging for Brain Conditions
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing the safety of a new imaging agent, [18F]3F4AP, in people with brain injuries, Alzheimer's Disease, and other forms of cognitive impairment. The goal is to see if this agent can help doctors better understand and treat these conditions.
Vitamin
Nicotinamide Riboside for Alzheimer's Disease
Recruiting1 awardPhase < 1
Belmont, Massachusetts
This trial is testing nicotinamide riboside (NR), a form of vitamin B3, to see if it can help people with early memory problems or mild Alzheimer's. The idea is that NR can boost a molecule called NAD+ in the brain, which helps cells produce energy and reduces stress. Researchers hope this will improve brain function in these patients. Nicotinamide riboside (NR) is a precursor to NAD+ and has shown potential in improving learning and memory in animal models of dementia.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alzheimer's & ALS
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial tests baricitinib, a pill taken daily, in people with early signs of Alzheimer's or ALS, or those at risk. The goal is to see if it can reduce harmful inflammation in the brain. Participants will take the medication for several months to check if it reaches the brain and lowers inflammation. Baricitinib is used for the treatment of rheumatoid arthritis and has shown promising preliminary data for moderate-to-severe atopic dermatitis.
Behavioral Intervention
Palliative Care Program for Alzheimer's Disease
Recruiting1 award2 criteria
Boston, Massachusetts
This trial will study if a program of dementia-specific palliative care, standardized caregiver education, and transitional care can reduce burdensome hospital transfers, improve symptom treatment and control, augment supportive services, and reduce nursing home transitions for patients, and improve caregiver outcomes of communication, shared decision-making and distress.
Radiopharmaceutical
Tau Tracer Comparison for Alzheimer's Disease
Recruiting1 awardPhase 1
Providence, Rhode Island
This trial uses special imaging agents to help visualize harmful brain proteins in people at risk of Alzheimer's disease. The agents make these proteins glow during scans, allowing doctors to see them clearly and monitor the disease.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.